Fingolimod
- Generic Name
- Fingolimod
- Brand Names
- Gilenya, Tascenso, Fingolimod Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H33NO2
- CAS Number
- 162359-55-9
- Unique Ingredient Identifier
- 3QN8BYN5QF
- Background
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was a...
- Indication
Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- Alternative Treatment
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
- Conditions
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT02939079
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT02720107
- Locations
- 🇩🇪
Novartis Investigative Site, Unterhaching, Germany
A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2017-09-13
- Target Recruit Count
- 5
- Registration Number
- NCT02490930
- Locations
- 🇺🇸
The Johns Hopkins University, Baltimore, Maryland, United States
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Conditions
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 111
- Registration Number
- NCT02342704
- Locations
- 🇬🇧
Research Site, Glasgow, Strathclyde, United Kingdom
Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
- Conditions
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 15
- Registration Number
- NCT02325440
- Locations
- 🇩🇪
Universitaetsklinikum Muenster, Department of Neurology, Muenster, Germany
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT02232061
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
- Conditions
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT02193217
- Locations
- 🇬🇧
Investigational site, Leeds, United Kingdom
Efficacy and Safety of FTY720 for Acute Stroke
- Conditions
- Interventions
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT02002390
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Safety and Efficacy of Fingolimod in MS Patients in China
- Conditions
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01941004
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 245
- Registration Number
- NCT01892722
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.